Buysiders will watch the performance of the wave of biotechs that priced IPOs in May and June as their 180-day lockup periods expire, which could be a useful indicator of investor appetite for more deals. Of the seven U.S.-listed companies that priced IPOs from January through April, five have traded down since their lockups ended (see "Post-Lockup Performance," A5). Below is a list of 180-day lockup expirations for 30 U.S.-listed IPOs over the next six months. Listed first to last